AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:AITB
Previous Symbol
CUSIPN/A
Phone972-8684-3313
Debt
Debt-to-Equity RatioN/A
Current Ratio4.54
Quick Ratio4.54
Price-To-Earnings
Trailing P/E Ratio-1.20
Forward P/E Ratio-3.87
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($3.01)
Net Income$-18,040,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-243.64%
Miscellaneous
Employees12
Outstanding Shares8,530,000
Market Cap$32.43 million
OptionableNot Optionable
AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions
What is AIT Therapeutics' stock symbol?
AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."
How were AIT Therapeutics' earnings last quarter?
AIT Therapeutics Inc (OTCMKTS:AITB) issued its quarterly earnings data on Wednesday, November, 14th. The company reported ($0.53) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.32. View AIT Therapeutics' Earnings History.
When is AIT Therapeutics' next earnings date?
What price target have analysts set for AITB?
1 brokers have issued 1 year target prices for AIT Therapeutics' stock. Their predictions range from $16.00 to $16.00. On average, they anticipate AIT Therapeutics' share price to reach $16.00 in the next twelve months. This suggests a possible upside of 344.4% from the stock's current price. View Analyst Price Targets for AIT Therapeutics.
What is the consensus analysts' recommendation for AIT Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AIT Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AIT Therapeutics.
Has AIT Therapeutics been receiving favorable news coverage?
Media headlines about AITB stock have trended somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AIT Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of AIT Therapeutics' key competitors?
Some companies that are related to AIT Therapeutics include RenovaCare (RCAR), Alphatec (ATEC), Endologix (ELGX), RA Medical Systems (RMED), Sensus Healthcare (SRTS), Restoration Robotics (HAIR), STRATA Skin Sciences (SSKN), Apollo Endosurgery (APEN), Invo Bioscience (IVOB), Repro-Med Systems (REPR), Arch Therapeutics (ARTH), Pro-Dex (PDEX), CAS Medical Systems (CASM), Motus GI (MOTS) and Obalon Therapeutics (OBLN).
Who are AIT Therapeutics' key executives?
AIT Therapeutics' management team includes the folowing people:
- Mr. Steven Adam Lisi, CEO & Chairman (Age 47)
- Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 44)
- Mr. Stephen J. DiPalma, Chief Financial Officer (Age 59)
- Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
- Dr. Giora Davidai M.D., Chief Medical Officer
How do I buy shares of AIT Therapeutics?
Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AIT Therapeutics' stock price today?
One share of AITB stock can currently be purchased for approximately $3.60.
How big of a company is AIT Therapeutics?
AIT Therapeutics has a market capitalization of $32.43 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.
What is AIT Therapeutics' official website?
How can I contact AIT Therapeutics?
AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.
MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
